Effects of Fractionated Radioimmunotherapy on Tumor Growth in Mice
Author Information
Author(s): Violet J A, Dearling J L J, Green A J, Begent R H J, Pedley R B
Primary Institution: Cancer Research UK Targeting and Imaging Group, University College London
Hypothesis
Does fractionating radioimmunotherapy improve its therapeutic efficacy and reduce toxicity?
Conclusion
Fractionated radioimmunotherapy causes less systemic toxicity but is less effective at treating tumors.
Supporting Evidence
- Fractionation reduced systemic toxicity as assessed by weight.
- Single administration showed better tumor control compared to fractionated doses.
- All treatment groups had a significant survival advantage over control mice.
Takeaway
This study looked at giving medicine in smaller doses over time instead of all at once, and found it was safer but didn't work as well for shrinking tumors.
Methodology
The study compared single versus fractionated doses of 131I-anti-CEA antibody in nude mice with human colorectal xenografts, assessing tumor growth and toxicity.
Potential Biases
Potential bias in the selection of treatment regimens and assessment methods.
Limitations
The study was limited to a specific mouse model and may not fully represent human responses.
Participant Demographics
Nude mice aged 2-3 months, weighing 23-27g.
Statistical Information
P-Value
0.033
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website